Table 1

Overall and stratified percentages of people living with HIV on treatment who reported being interested in trying a novel long-acting HIV treatment (n=688)

Characteristic	Independent variable	Categories of independent variable	N	Interest in trying LAR (outcome)
		Total	688	65.8
Demographic characteristics	Gender	Female	229	66.8
		Male	457	65.4
		Other	2	*
	Sexual orientation	Heterosexual	233	67.8
		Homosexual	417	67.1
		Other	38	39.5
	Age (years)	<50	484	69.8
	Age (years)	50+	204	56.4
	Marital status	Single	273	69.6
		With partner	351	65.5
		Other/unknown	64	51.6
		Postgraduate	134	63.4
	Education	College	392	69.1
		GCSE	99	67.7
		Other/unknown	63	47.6
	Employment	Employed	457	70.0
	Employment	Non-employed/unknown	231	57.6
	Country of residence	France	144	59.7
		Germany	198	67.2
		Italy	150	64.0
		UK	196	70.4
	Year of HIV diagnosis	2017–2019	88	84.1
		2010–2016	286	67.1
		Pre-2010	314	59.6
	Nativity status†	Foreign-born	259	76.4
	Nativity status†	Native-born	429	59.4
Current ART type‡	NNRTI-containing regimen	Not reported	450	68.4
	NNRTI-containing regimen	Reported	238	60.9
	Entry inhibitor-containing regimen	Not reported	661	65.8
	Entry inhibitor-containing regimen	Reported	27	66.7
	Protease inhibitor-containing regimen	Not reported	538	64.9
	Protease inhibitor-containing regimen	Reported	150	69.3
	Any integrase strand inhibitor-containing regimen	Not reported	300	66.3
		Reported	388	65.5
	Dolutegravir	Not reported	494	66.0
		Reported	194	65.5
	Elvitegravir	Not reported	667	65.7
		Reported	21	71.4
	Raltegravir	Not reported	620	65.8
		Reported	68	66.2
	Bictegravir	Not reported	564	66.5
		Reported	124	62.9
Emotional challenges regarding daily oral dosing	Daily oral ART routine stressful	Not reported	565	63.2
	Daily oral ART routine stressful	Reported	123	78.0
	Remembering to take dose at exact time every day stressful	Not reported	500	61.6
	Remembering to take dose at exact time every day stressful	Reported	188	77.1
	Daily oral ART cues bad memories	Not reported	378	59.3
	Daily oral ART cues bad memories	Reported	310	73.9
	Worried about missing daily oral ART	Not reported	412	61.4
	Worried about missing daily oral ART	Reported	276	72.5
	Wish to forget about HIV	Not reported	430	60.7
		Reported	258	74.4
	Wish HIV were a smaller part of their life	Not reported	342	57.3
	Wish HIV were a smaller part of their life	Reported	346	74.3
	Perception daily oral ART limits day-to-day life	Not reported	525	62.9
	Perception daily oral ART limits day-to-day life	Reported	163	75.5
	Perception daily oral ART disrupts work	Not reported	593	64.1
	Perception daily oral ART disrupts work	Reported	95	76.8
	Perception daily oral ART disrupts leisure activities	Not reported	560	63.6
	Perception daily oral ART disrupts leisure activities	Reported	128	75.8
	Worried about detectable viral load from missing daily ART	Not reported	400	59.5
	Worried about detectable viral load from missing daily ART	Reported	288	74.7
	Worried of transmitting HIV from missing daily ART	Not reported	465	60.2
	Worried of transmitting HIV from missing daily ART	Reported	223	77.6
	Wish they did not have to take HIV medicines every day	Not reported	292	59.2
	Wish they did not have to take HIV medicines every day	Reported	396	70.7
	Perception of stigma from daily oral dosing	Not reported	413	54.2
	Perception of stigma from daily oral dosing	Reported	275	83.3

The analyses in this descriptive table aimed to provide estimates of interest in switching to long-acting HIV treatment among the entire population and specified subgroups.
*Estimates suppressed because of small sample size.
†‘Native-born’ if born in the surveyed country, ‘foreign-born’ if otherwise.
‡Categories not mutually exclusive. Information was collected on the specific HIV medications respondents were currently taking; this was classified based on the core agent reported (non-mutually exclusive categories), as an integrase strand transfer inhibitor [INSTI], a boosted protease inhibitor [PI], or a non-nucleoside reverse transcriptase inhibitor [NNRTI]. NNRTI-containing regimens included ‘Atripla or generics (emtricitabine/efavirenz/tenofovir disoproxil fumarate)’; ‘Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)’; ‘Edurant (rilpivirine)’; ‘Eviplera (emtricitabine/rilpivirine/tenofovir-disoproxil fumarate)’; ‘Viramune or generics (Nevirapin)’; ‘Sustiva or generics (efavirenz)’; ‘Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide)’ or ‘Pifeltro (doravirine)’. PI-containing regimens included ‘Kaletra (lopinavir/ritonavir)’; ‘Evotaz (atazanavir/cobicistat)’; ‘Prezista (darunavir)’; ‘Reyataz (atazanavir)’; ‘Rezolsta (darunavir/cobicistat)’ or ‘Symtuza (darunavir/emtricitabine/tenofovir alafenamide)’. INSTI-containing regimens included ‘Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)’; ‘Tivicay (dolutegravir)’; ‘Triumeq (dolutegravir/abacavir/lamivudine)’; ‘Isentress (raltegravir)’; ‘Juluca (dolutegravir/rilpivirine)’; ‘Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) or ‘Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)’.
ART, antiretroviral therapy; CNS, central nervous system; GCSE, General Certificate of Secondary Education; HCP, healthcare professional; INSTI, integrase strand transfer inhibitor; LAR, long-acting regimen; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitor.